Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.

Evans-Jones JG, Cottle LE, Back DJ, Gibbons S, Beeching NJ, Carey PB, Khoo SH.

Clin Infect Dis. 2010 May 15;50(10):1419-21. doi: 10.1086/652149.

2.

Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies.

Donato MT, Montero S, Castell JV, Gómez-Lechón MJ, Lahoz A.

Anal Bioanal Chem. 2010 Mar;396(6):2251-63. doi: 10.1007/s00216-009-3441-1. Epub 2010 Feb 10.

PMID:
20145913
3.

Variability in drug metabolizing enzyme activity in HIV-infected patients.

Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, Hein DW, van der Horst C, Kashuba AD.

Eur J Clin Pharmacol. 2010 May;66(5):475-85. doi: 10.1007/s00228-009-0777-6. Epub 2010 Jan 19.

4.

Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.

Maartens G, Decloedt E, Cohen K.

Antivir Ther. 2009;14(8):1039-43. doi: 10.3851/IMP1455. Review.

PMID:
20032533
5.

The cost and incidence of prescribing errors among privately insured HIV patients.

Hellinger FJ, Encinosa WE.

Pharmacoeconomics. 2010;28(1):23-34. doi: 10.2165/11313810-000000000-00000.

PMID:
20014874
6.

Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance.

MacDonald L, Murty M, Foster BC.

Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):563-78. doi: 10.1517/17425250902942302. Review.

PMID:
19442034
7.

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.

Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, Mangin E, Marbury TC, Berg JK, Chodakewitz JA, Stone JA, Gottesdiener KM, Wagner JA, Iwamoto M.

Antimicrob Agents Chemother. 2009 Jul;53(7):2852-6. doi: 10.1128/AAC.01468-08. Epub 2009 May 11.

8.

Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable.

Seden K, Back D, Khoo S.

J Antimicrob Chemother. 2009 Jul;64(1):5-8. doi: 10.1093/jac/dkp152. Epub 2009 Apr 27. Review.

9.

Clinical management of drug interaction with antiretroviral agents.

Pau AK.

Curr Opin HIV AIDS. 2008 May;3(3):319-24. doi: 10.1097/COH.0b013e3282f82c06.

PMID:
19372985
10.

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.

Dickinson L, Khoo S, Back D.

Curr Opin HIV AIDS. 2008 May;3(3):296-305. doi: 10.1097/COH.0b013e3282f82bf1.

PMID:
19372982
11.

Pharmacogenetics of antiretroviral agents.

Owen A, Khoo SH.

Curr Opin HIV AIDS. 2008 May;3(3):288-95. doi: 10.1097/COH.0b013e3282f7cda4.

PMID:
19372981
12.

Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.

Ramanathan R, Pau AK, Busse KH, Zemskova M, Nieman L, Kwan R, Hammer JH, Mican JM, Maldarelli F.

Clin Infect Dis. 2008 Dec 15;47(12):e97-9. doi: 10.1086/593314.

13.

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.

Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G.

JAMA. 2008 Aug 6;300(5):530-9. doi: 10.1001/jama.300.5.530.

PMID:
18677025
14.

Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature.

Foisy MM, Yakiwchuk EM, Chiu I, Singh AE.

HIV Med. 2008 Jul;9(6):389-96. doi: 10.1111/j.1468-1293.2008.00579.x. Epub 2008 May 4. Review.

15.

Evaluation of frequently used drug interaction screening programs.

Vonbach P, Dubied A, Krähenbühl S, Beer JH.

Pharm World Sci. 2008 Aug;30(4):367-74. doi: 10.1007/s11096-008-9191-x. Epub 2008 Apr 16.

PMID:
18415695
16.

Frequency of HIV-related medication errors and associated risk factors in hospitalized patients.

Pastakia SD, Corbett AH, Raasch RH, Napravnik S, Correll TA.

Ann Pharmacother. 2008 Apr;42(4):491-7. doi: 10.1345/aph.1K547. Epub 2008 Mar 18.

PMID:
18349307
17.

Drug-drug interaction programs in clinical practice.

Pham PA.

Clin Pharmacol Ther. 2008 Mar;83(3):396-8. doi: 10.1038/sj.clpt.6100504. Review.

PMID:
18285786
18.

Drug-related problems in hospitalized patients with HIV infection.

Mok S, Minson Q.

Am J Health Syst Pharm. 2008 Jan 1;65(1):55-9.

PMID:
18159040
19.

Interactions between protease inhibitors and acid-reducing agents: a systematic review.

Béïque L, Giguère P, la Porte C, Angel J.

HIV Med. 2007 Sep;8(6):335-45. Review.

20.

Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy.

Babb DA, Pemba L, Seatlanyane P, Charalambous S, Churchyard GJ, Grant AD.

Psychol Health Med. 2007 May;12(3):314-20.

PMID:
17510901
Items per page

Supplemental Content

Write to the Help Desk